Vintafolide

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameVintafolide
Drug Alias Name长春福肽vintafolidaFolate-DAVLBH长春夫利vintafolidum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin modulatorsFolate receptor beta agonistsFolate receptor alpha agonists
TargetsFolate receptor betaFolate receptor alphaTubulin
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co IncEndocyte Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeL01CA06
Related LinksWikipediaKEGG